Johnson & Johnson Medical Devices Companies’ arm DePuy Synthes, via French affiliate Apsis S.A.S., has recently announced that it has taken over a private firm, Orthotaxy, that specializes in the development of software-enabled surgery technologies.
If reports are to be believed, Johnson & Johnson, with this acquisition is aiming to build a next-generation robotic-arm assisted orthopedic surgery solution for the healthcare & medical devices industry that is time-efficient, cost-efficient, and user friendly in a variety of medical care settings.
J&J’s growing attention towards surgical robotics has not come as a major surprise in healthcare & medical devices market, apparently. It is in fact being speculated that the company will penetrate further in surgical robotics market, on the cusp of its partnership with Verily – Google’s life sciences unit. Reportedly, the joint entity named as the Verb, will be working on developing myriad types of surgical robotics platform.
Reports cite that Orthotaxy’s robotic-assisted surgery solution is still in the nascent stage of development for partial and total knee replacement, and J&J in this regard is planning to broaden its application spectrum to thrive in the healthcare & medical devices industry.
In a company statement, Ciro Rӧmer, Company Group Chairman of DePuy Synthes and the orthopedics business of J&J, was quoted stating that the company aims to bring robotic-assisted surgery technology to the mass market in order to deliver value-based services to the physicians, patients, and other healthcare providers across the region. He further added that leveraging Orthotaxy’s expertise in developing orthopedic surgical solutions will in turn help J&J to increase patient satisfaction and clinical outcomes.
Sources revealed that J&J Medical Devices Companies is also planning to focus on digital technology solutions that would provide the best-in-class products across the entire continuum of healthcare & medical devices industry.
For the record, the financial terms of the transaction between J&J and Orthotaxy have not yet been disclosed.